Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells.
Ibáñez-Navarro M, Fernández A, Escudero A, Esteso G, Campos-Silva C, Navarro-Aguadero MÁ, Leivas A, Caracuel BR, Rodríguez-Antolín C, Ortiz A, Navarro-Zapata A, Mestre-Durán C, Izquierdo M, Balaguer-Pérez M, Ferreras C, Martínez-López J, Valés-Gómez M, Pérez-Martínez A, Fernández L. Ibáñez-Navarro M, et al. Among authors: leivas a. Front Immunol. 2023 Oct 18;14:1187665. doi: 10.3389/fimmu.2023.1187665. eCollection 2023. Front Immunol. 2023. PMID: 37928520 Free PMC article.
Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L, Metais JY, Escudero A, Vela M, Valentín J, Vallcorba I, Leivas A, Torres J, Valeri A, Patiño-García A, Martínez J, Leung W, Pérez-Martínez A. Fernández L, et al. Among authors: leivas a. Clin Cancer Res. 2017 Oct 1;23(19):5824-5835. doi: 10.1158/1078-0432.CCR-17-0075. Epub 2017 Jun 28. Clin Cancer Res. 2017. PMID: 28659311
GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L, Fernández A, Mirones I, Escudero A, Cardoso L, Vela M, Lanzarot D, de Paz R, Leivas A, Gallardo M, Marcos A, Romero AB, Martínez-López J, Pérez-Martínez A. Fernández L, et al. Among authors: leivas a. Front Immunol. 2019 Oct 10;10:2361. doi: 10.3389/fimmu.2019.02361. eCollection 2019. Front Immunol. 2019. PMID: 31649672 Free PMC article.
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. Leivas A, et al. Blood Cancer J. 2021 Aug 14;11(8):146. doi: 10.1038/s41408-021-00537-w. Blood Cancer J. 2021. PMID: 34392311 Free PMC article.
Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits.
Fernández A, Pérez-Martínez A, Escudero A, Mirones I, González B, de Paz R, Matamala N, Clares L, Navarro A, Galán V, Martínez-Romera I, Martínez-López J, Leivas A, Valés-Gómez M, Ferreras C, Fernández L. Fernández A, et al. Among authors: leivas a. Leuk Lymphoma. 2022 Aug;63(8):1970-1974. doi: 10.1080/10428194.2022.2057490. Epub 2022 Apr 3. Leuk Lymphoma. 2022. PMID: 35369829 No abstract available.
Overcoming tumor resistance mechanisms in CAR-NK cell therapy.
Valeri A, García-Ortiz A, Castellano E, Córdoba L, Maroto-Martín E, Encinas J, Leivas A, Río P, Martínez-López J. Valeri A, et al. Among authors: leivas a. Front Immunol. 2022 Aug 3;13:953849. doi: 10.3389/fimmu.2022.953849. eCollection 2022. Front Immunol. 2022. PMID: 35990652 Free PMC article. Review.
Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
Vela M, Corral D, Carrasco P, Fernández L, Valentín J, González B, Escudero A, Balas A, de Paz R, Torres J, Leivas A, Martinez-Lopez J, Pérez-Martínez A. Vela M, et al. Among authors: leivas a. Cancer Lett. 2018 May 28;422:107-117. doi: 10.1016/j.canlet.2018.02.033. Epub 2018 Feb 23. Cancer Lett. 2018. PMID: 29477379 Clinical Trial.
Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia.
Gómez García LM, Escudero A, Mestre C, Fuster Soler JL, Martínez AP, Vagace Valero JM, Vela M, Ruz B, Navarro A, Fernández L, Fernández A, Leivas A, Martínez-López J, Ferreras C, De Paz R, Blanquer M, Galán V, González B, Corral D, Sisinni L, Mirones I, Balas A, Vicario JL, Valle P, Borobia AM, Pérez-Martínez A. Gómez García LM, et al. Among authors: leivas a. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):328-337.e1. doi: 10.1016/j.clml.2021.01.013. Epub 2021 Jan 25. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33610500 Clinical Trial.
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.
Leivas A, Risueño RM, Guzmán A, Sánchez-Vega L, Pérez M, Megías D, Fernández L, Alonso R, Pérez-Martínez A, Rapado I, Martínez-López J. Leivas A, et al. Cancer Immunol Immunother. 2021 Oct;70(10):2911-2924. doi: 10.1007/s00262-021-02901-y. Epub 2021 Mar 10. Cancer Immunol Immunother. 2021. PMID: 33693963 Free PMC article.
36 results